Bio Pharma Dive

AUGUST 25, 2022

On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.

Gene Therapy 246

Gene Therapy Gene Marketing 246

Bio Pharma Dive

AUGUST 28, 2020

A draft report from the drug pricing watchdog concluded that, under the right conditions, Roctavian may be cost-effective at a price of $2.5

Gene Therapy 300

Gene Therapy Gene Drugs 300

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. BioMarin previously said that the treatment’s European price would likely be around EUR1.5 million price tag.

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

pharmaphorum

AUGUST 26, 2022

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years.

Gene Therapy 109

Gene Therapy Gene Antibody Marketing 109

Pharmaceutical Technology

JANUARY 27, 2023

Other companies like BioMarin have already announced an intention to offer an outcomes-based warranty program for its hemophilia A drug Roctavian (valoctocogene roxaparvovec). In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130